| Sign In to gain access to subscriptions and/or personal tools. |
Review: Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension?Division of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, Scotland, UK, j.l.reid{at}clinmed.gla.ac.uk
Angiotensin II receptor blockers (ARBs) may produce a number of molecule-specific effects that appear to be independent of interaction with the angiotensin II type 1 (AT 1)-receptor. These include antagonism of the thromboxane A2 receptor, inhibition of platelet aggregation, induction of peroxisome proliferator-activated receptor gamma (PPAR
Key Words: hypertension • angiotensin II antagonists • thromboxane A2 receptor • platelet aggregation • PPAR
Journal of Renin-Angiotensin-Aldosterone System, Vol. 6, No. 1,
15-24 (2005) This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
) activity, and reduction of serum uric acid levels. However, definitive evidence is lacking that these molecule-specific effects give rise to a therapeutic advantage of one ARB over another. Currently, the possibility of a link between a molecule-specific effect of an ARB and an improvement in clinical outcomes is best illustrated by a reduction in serum uric acid levels with losartan. Data from Losartan Intervention For Endpoint reduction in hypertension (LIFE) study suggest treatment-induced decrease in serum uric acid may contribute to the treatment benefit of a losaran-based versus atenolol-based therapy on the composite endpoint (death, myocardial infarction, or stroke). This finding should prompt further studies to investigate the long-term cardioprotective benefits issue of reducing hyperuricaemia in hypertensive patients. 
